I am a minority of one and have consistently said: 1) Vaccines could theoretically never work against this coronavirus, because it is so like the common cold, and 2) Finding anti-viral re-purposed drugs (which we humorously named Anti-Bat) was the way ahead. End of story. So what will the future bring? Just more of the same bickering from all concerned in the health industry! 
The Playground
-
-
Meanwhile, while we sit back and debate, Vladimir Putin is about to detonate.
-
In another rebuf to Huxley and his band of experts. I said in August of 2020 that the gut and body pH will tell the tale of Covid severity. Vitamin D deficiency leads to bad gut Microbiome, I was laughed off by Mr. Magority. I have one thing to say. I TOLD YOU SO!!!! Take a B complex vitamin along with your anti bat!!!!
Lael Yonker & Team at Mass General Report AT-1001 May Treat COVID-19 Triggered MIS-C in Children
Lael Yonker & Team at Mass General Report AT-1001 May Treat COVID-19 Triggered MIS-C in ChildrenFollowing several studies investigating a troubling condition associated with children and COVID-19 called multi-inflammatory syndrome in childrentrialsitenews.comFollowing several studies investigating a troubling condition associated with children and COVID-19 called multi-inflammatory syndrome in children (MIS-C), Lael Yonker, a pediatric pulmonary physician-scientist at Mass General for Children, and her colleagues report on a possible breakthrough drug candidate called larazotide acetate (AT-1001) seemingly targeting MIS-C via a gut mechanism of action. Sponsored by Massachusetts General Hospital and Brigham and Women’s Hospital, the promising case series are being put to the test via a Phase 2 clinical trial: the Boston-based team now investigates the drug for stronger medicinal evidence.
Published recently in the journal Clinical Care Explorations, Dr. Yonker and team report that of the 6,431 children diagnosed with MIS-C since May 2020 in the United States, 55 have died, according to the U.S. Centers for Disease Control and Prevention (CDC). Previously, an MGH and BWH study revealed that the SARS-CoV-2 virus can remain in the gut for weeks to months.
TrialSite has followed other studies indicating emerging evidence of a gut connection to SARS-CoV-2 including the work and Professor Siew C. NG at the Chinese University of Hong Kong.
Boston Teams Pursue Answers
Summarizing their latest results, the most recent case series authors, led by Yonker, note that when the novel coronavirus persists in the gut, an impaired mucosal barrier can allow small viral particles such as the spike protein to enter the bloodstream. This can lead to infections such as COVID-19 and in some cases, hyperinflammatory responses that trigger MIS-C.
Early Moves
Yonker, a pediatric pulmonary physician-scientist, uncovered the potential of larazotide (AT-1001), thanks to a collaboration with the drug’s inventor, Alessio Fasano, MD, director of the Mucosal Immunology and Biology Research Center and chief of the Division of Pediatric Gastroenterology and Nutrition at MHGfc.
Given the urgency at the time, Yonker and Fasano applied to the FDA for emergency compassionate use for treating MIS-C by February 2021. This move led the way to treat the children, the basis for the team’s first case series.
Treating several severely ill MIS-C patients who failed to respond to prescribed therapies, the Boston-based team published the first positive results in July 2021.
The Drug
In this recent review of a case series study, the Boston teams administered the drug larazotide acetate to four extremely ill children ranging from age 3 to 17 at the time under treatment for MIS-C at MGH.
The authors report that the drug decreases the release of a molecule (zonulin) that associates with gut permeability and an impaired mucosal barrier. The physician-research team would assess the efficacy of larazotide acetate, and according to one paper, it is “the most promising pharmaceutical drug candidate for the treatment of altered intestinal barrier function.”
Yonker now leads a Phase 2 study (NCT05022303) investigating the efficacy and safety of AT1001 versus placebo in pediatric patients with SARS-CoV-2 infection who experience early signs of MIS-C and face a high risk of condition progression.
An ongoing Phase 3 study sponsored by the drug’s maker, 9 Meters Biopharma, investigates for efficacy against Celiac disease. This Research Triangle-based biotech is pioneering novel gut therapies via a secure license to the intellectual property.
Promising Data from Case Series
The study team summarized the case series finding that the investigational product decreases the release of zonulin, again a molecule that can lead to increased gut permeability and an impaired mucosal barrier. The researchers compared the clinical outcomes of the four children who received larazotide plus steroids and intravenous immune globulin (IVIG) to 22 children who received only steroids and IVIG.
The children who received four daily oral doses of larazotide acetate had a significantly faster resolution of gastrointestinal symptoms and a slightly shorter hospital stay. Serum levels of the highly inflammatory spike protein associated with the SARS-CoV-2 virus dropped much more quickly in children treated with larazotide, clearing from the blood within one day, versus 10 days for children not treated with larazotide.
The authors noted, “These findings suggest that larazotide may provide a safe and beneficial adjuvant therapy for the treatment of MIS-C.” Lael Yonker, MD, pediatric pulmonologist and director of the Cystic Fibrosis Center at MassGeneral Hospital for Children (MGHfC) went on the record “Our results demonstrate the urgent need for the development of diagnostic and prognostic tools to advance our understanding and treatment of this devastating disease.”
In the hierarchy of medicinal evidence, a case series, which is an article that physicians or other relevant scientists write about patients with a specific diagnosis, is categorized as level 4 evidence. Led by Lael Yonker, MD, Massachusetts General Hospital, the research team continues to study larazotide in Phase 2 clinical trials.
A Key Expert at MGH
The expertise of Dr. Fasano made this breakthrough possible. An expert in celiac disease and autoimmune disorders, Fasano developed larazotide acetate in the early 2000s as an adjunctive treatment for celiac disease. Thanks to Fasano’s deep expertise with the drug and his teaming with Yonker, the study team was able to execute a clinical “proof of concept” randomized, double-blind, placebo-controlled study in August 2021 investigating the efficacy of the drug in hospitalized MIS-C patients.
Lead Research/Investigator
Lael Yonker, MD pediatric pulmonologist and director of the Cystic Fibrosis Center at MassGeneral Hospital for Children (MGHfC).
David Walt, Ph.D., principal investigator of the Walt Laboratory in Brigham’s Department of Pathology.
Other team members can be viewed at study source.
Researchers identify a promising drug for treating serious COVID-19 complication in children
Researchers identify a promising drug for treating serious COVID-19 complication in children
Relationships Between Vitamin D, Gut Microbiome, and Systemic Autoimmunity
Relationships Between Vitamin D, Gut Microbiome, and Systemic AutoimmunityThere is increasing recognition of the role the microbiome plays in states of health and disease. Microbiome studies in systemic autoimmune diseases…www.frontiersin.org -
It's all in the gut and it starts with vitamin D .
‘Glitch’ in Type I Interfere Signaling Associates with Severe COVID-19 Disease
‘Glitch’ in Type I Interfere Signaling Associates with Severe COVID-19 DiseaseCould it be that an actual glitch in type 1 interferon (IFN) signaling is associated with people who experienced more severe SARS-CoV-2 diseasetrialsitenews.comCould it be that an actual glitch in type 1 interferon (IFN) signaling is associated with people who experienced more severe SARS-CoV-2 disease progression? Put another way, was an individual, case by case abnormal reaction the explanation behind why some people get deathly ill behind COVID-19 while others don’t even notice they’re sick? The recent COVID Human Genetic Effort (CHGE) study may have some answers.
Set up in February 2020 by Jean-Laurent Casanova of Rockefeller University and Helen Su of the National Institute of Allergy and Infectious Diseases (NIAID), the study team sought to better understand why some COVID-19 patients become deathly ill while others are asymptomatic. TrialSite provides a research breakdown of this lab work conducted in the laboratory of infectious diseases of Jean-Laurent Casanova and Laurent Abel.
Where did this research occur?
France and the USA.
What’s the source of the data?
Biosamples from a large number of patients in France. Researcher Paul Bastard, winner of the inaugural Michelson Philanthropies & Science Prize for Immunology rode his bike to Paris hospitals to collect the samples as part of the study.
What did the results of the analyses reveal?
After conducting sequencing studies from a large pool of the samples, the study authors found consistently that hospitalized patients suffering from severe COVID-19 had a glitch in type I interferon (IFN) signaling.
Normally, Type I IFNs are secreted by infected cells to help fight off viruses. Yet in some of the patients, the research team found that they developed an autoimmune response with autoantibodies attacking type I IFNs blocking their antiviral effect. This abnormal reaction can contribute to worsening SARS-CoV-2-triggered conditions.
What’s the research takeaway?
Specific autoantibody responses against IFN could be a driver triggering more severe COVID-19, particularly in older patients but also in younger people who present with life-threatening COVID-19. Could this be a clue as to why COVID-19 is fatal for some and not others?
Is age also a factor?
Yes. The study team reports that the triggering of autoantibodies against IFNs in COVID-19 patients appears to intensify with age.
What precision-therapy-based advancement is now possible?
A screening tool that could help identify patients facing the highest risk of life-threatening complications.
According to Researcher Paul Bastard, a technique called ELISA could possibly be employed for screening autoantibodies against type I IFNs.
What other factors did the team identify based on the French samples?
One potential second factor associated with severe COVID-19 outcomes includes a rare mutation in genes controlling for type I IFNs. The authors noted that a gene that encodes the receptor TLR7, involved in initiating type I IFN responses, is also screen able—although more challenging.
What is COVID Human Genetic Effort (CHGE)?
CHGE or the COVID Human Genetic Effort is an international consortium aiming to discover the human genetic and immunological bases of the various clinical forms of SARS-CoV-2 infection. CHGE searches for:
(I) Monogenic or digenic inborn errors of immunity (IEI), rare or common, underlying severe forms of COVID-19 in previously healthy individuals, including severe pneumonia, multisystem inflammatory syndrome in children (MIS-C), Long COVID, COVID Toes, etc.
(ii) Phenocopies of these monogenic IEI, such as auto-antibodies neutralizing gene products of loci whose variants underlie these IEI (e.g., auto-antibodies to type I IFNs mimicking inborn errors of type I IFNs).
(iii) Single-gene variants, rare or common, which make certain individuals resistant to the infection by the SARS-CoV2 itself, despite repeated exposure, or resistant to the development of clinical manifestations despite infection.
With these three projects, the COVID Human Genetic Effort aims to discover truly causative genetic and/or immunological anomalies, rare or common, and decipher in depth the molecular, cellular, and immunological mechanisms by which they cause resistance to viral infection or disease, or predisposition to one or another form of severe disease (Casanova JL & Su HC Cell 2020).
Lead Research/investigator
Paul Bastard, PhD, Imagine Institute, INSERM, University of Paris
Jean-Laurent Casanova, MD, PhD, Rockefeller University
Helen Su, MD, PhD, National Institute of Allergy and Infectious Diseases
Prize-Winning Work Informs Who Is Most At-Risk from COVID-19For illuminating factors that underlie varied susceptibility to COVID-19, Paul Bastard is the grand prize winner of the inaugural Michelson Philanthropies &…www.aaas.orgTonic interferon restricts pathogenic IL-17-driven inflammatory disease via balancing the microbiome
Tonic interferon restricts pathogenic IL-17-driven inflammatory disease via balancing the microbiomeOverlapping action of type I, II, and III interferons maintains microbiome homeostasis, prevents IL-17-driven myeloproliferative disease, and protects against…elifesciences.orgType I and III Interferon in the Gut: Tight Balance between Host Protection and Immunopathology
Type I and III Interferon in the Gut: Tight Balance between Host Protection and ImmunopathologyThe intestinal mucosa forms an active interface to the outside word, facilitating nutrient and water uptake and at the same time acts as a barrier toward the…www.ncbi.nlm.nih.govRelationships Between Vitamin D, Gut Microbiome, and Systemic Autoimmunity
Relationships Between Vitamin D, Gut Microbiome, and Systemic AutoimmunityThere is increasing recognition of the role the microbiome plays in states of health and disease. Microbiome studies in systemic autoimmune diseases…www.frontiersin.orgVitamin D deficiency changes the intestinal microbiome reducing B vitamin production in the gut. The resulting lack of pantothenic acid adversely affects the immune system, producing a "pro-inflammatory" state associated with atherosclerosis and autoimmunity
-
Vladimir Putin is about to detonate.
Putin just did set (watch BCC) the nuclear strategic force on highest alert (= pre launch phase) His face shows deep traces of chemo therapy damage. He is out of body, just a victim of his dark soul. Let's hope the own people liquidate him soon. Else nobody will stop Dr. Strangelove...as he already lost the Ukraine war game.
-
Still the worst reads to citations ratio in Researchgate history… the reason is obvious. Click farms can’t cite.
Dear Dr Rossi,
It is stunning about your publications on Researchgate also the number of Reccomendations, that in the last week reached the impressive number over 6900: I observed in your profile watching
http://www.researchgate.net/publication/330601653_E-Cat_SK_and_Iong_range_particle_interactions
that in the last 10 days the reccomendations have strongly increased.
Do you have an idea why ?
Cheers
Prof
Prof:
I too took note of this fact. I have not idea about the reason.
Warm Regards,
A.R.
-
https://rumble.com/embed/vr73cs/?pub=qdzr7"
This graphics shows that the CoV-19-death/case relation (red=deaths) did decouple before vaccination started. So vaccination never did save any live, It was natural immunity as we say since a long time.
Video:: https://rumble.com/embed/vr73cs/?pub=qdzr7
Aus::
Dispelling the Myth of a Pandemic of the Unvaccinated – Canadian Covid Care Alliance
-
New Study: mRNA Vaccines Alter Human Liver DNA In Vitro?
New Study: mRNA Vaccines Alter Human Liver DNA In Vitro?Pfizer’s BioNTech vaccine causes intracellular reverse transcription of BNT162b2 mRNA into human DNA in vitro, renewing concerns that vaccines maytrialsitenews.comPfizer’s BioNTech vaccine causes intracellular reverse transcription of BNT162b2 mRNA into human DNA in vitro, renewing concerns that vaccines may introduce spike protein into the nuclei of cells.
The findings emerged Friday in a peer-reviewed article entitled “Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line” in the Current Issues in Molecular Biology Journal, an imprint of MDPI, the largest open-access publisher in the world and the fifth-largest publisher overall in terms of journal paper output.
Researchers Warn: Pfizer Vaccine May Affect Integrity of Genomic DNA
“Our study shows that BNT162b2 can be reverse transcribed to DNA in liver cell line Huh7, and this may give rise to the concern if BNT162b2-derived DNA may be integrated into the host genome and affect the integrity of genomic DNA, which may potentially mediate genotoxic side effects,” the authors warn.
The study, authored by a team of Swedish researchers at Lund University, concluded that Pfizer’s COVID-19 mRNA vaccine entered the human liver cell line Huh7 in vitro and BNT162b2 mRNA was subsequently transcribed intracellularly into DNA within six hours of exposure.
An “Immortal” Human Cell Line
The Huh7 cell line is a permanent line of liver cells derived from male hepatoma tissue that was surgically removed from a 57-year-old Japanese man in 1982. For the next 40 years, Huh7 and its derivatives were used in thousands of laboratories across the planet as a convenient experimental substitute for primary hepatocytes.
Hepatocytes, the major parenchymal cells in the liver, play pivotal roles in metabolism, detoxification, and protein synthesis. Hepatocytes also activate innate immunity against invading microorganisms by secreting innate immunity proteins.
In Vitro Vs. In Vivo Caveats
Researchers who conduct in vitro studies commonly remind that results that emerge from laboratories and test tubes often differ from results which are derived in living, fully intact organisms. And the Huh7, itself, has limitations that could introduce errors or anomalies into laboratory results.
Still, the study conducted by researchers at one of Europe’s oldest and most prestigious research institutions raises serious questions about Pfizer’s mRNA vaccines’ impact on human DNA, which have yet to be subjected to the typical years-long (or decades-long) battery of long-term safety monitoring protocols.
Changes in Gene Expression of LINE-1
The study authors exposed Huh7 cells to Pfizer’s BNT162b2 mRNA and then performed a quantitative polymerase chain reaction on RNA extracted from the cells. The research team discovered high levels of BNT162b2 in Huh7 cells and changes in gene expression of long interspersed nuclear element-1, or LINE-1, which is an endogenous reverse transcriptase.
BNT162b2 mRNA Reverse Transcribed Into DNA Within Six Hours Of Exposure
The authors conclude that BNT162b2 transfects into human liver cell line huh7 in vitro, altering LINE-1 expression and distribution. The authors also find that “BNT162b2 mRNA is reverse transcribed intracellularly into DNA in as fast as six hours upon BNT162b2 exposure.”
BNT162b2 is a lipid nanoparticle (LNP)–encapsulated, nucleoside-modified RNA vaccine (modRNA) which resembles gene therapy platforms. Pfizer’s mRNA vaccine encodes the full-length of SARS-CoV-2 spike protein. That spike protein is modified by two proline mutations to ensure antigenically optimal pre-fusion conformation, mimicking the intact virus to elicit virus-neutralizing antibodies.
A recent study showed that SARS-CoV-2 RNAs can be reverse-transcribed and integrated into the genome of human cells, which the authors said led them to investigate whether spike transfected by mRNA vaccines might have comparable effects.
CDC Says mRNA Vaccines Does Not Enter Nuclei or Interact With DNA
mRNA vaccines were not designed to invade human cells’ nuclei. In fact, the United States Centers for Disease Control claimed in December that “COVID-19 vaccines do not change or interact with your DNA in any way.”
“The genetic material delivered by mRNA vaccines never enters the nucleus of your cells, which is where your DNA is kept,” the government agency website said. “Viral vector COVID-19 vaccines deliver genetic material to the cell nucleus to allow our cells to build protection against COVID-19. However, the vector virus does not have the machinery needed to integrate its genetic material into our DNA, so it cannot alter our DNA.”
The Nucleus is the “Brain” of Human Cells, Site of DNA Replication
Some biologists refer to the nucleus, metaphorically, as the “brain” of the cell. The nucleus is the most prominent of cells’ organelles and contain genetic information in the form of deoxyribonucleic acid (DNA) and is the site of DNA replication. The nucleus is also the site for the synthesis of ribonucleic acid (RNA) which is the template for synthesis of other cell proteins and for protein factories of the cell called ribosomes.
Transfection of spike protein into the nucleus opens the possibility of DNA modification, the authors wrote.
mRNA Vaccines Effect on “Genomic Integrity” Should Be Studied
“At this stage, we do not know if DNA reverse transcribed from BNT162b2 is integrated into the cell genome,” the authors wrote. “Further studies are needed to demonstrate the effect of BNT162b2 on genomic integrity, including whole genome sequencing of cells exposed to BNT162b2, as well as tissues from human subjects who received BNT162b2 vaccination
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell LinePreclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the…www.mdpi.com -
Still the worst reads to citations ratio in Researchgate history…
Why do you visit his site?? For me this would be a crazy idea....
-
The Good Life.
External Content youtu.beContent embedded from external sources will not be displayed without your consent.Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy. -
Another anti bat, pepcid!
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trialObjective We assessed whether famotidine improved inflammation and symptomatic recovery in outpatients with mild to moderate COVID-19. Design Randomised,…gut.bmj.comAbstract
Objective We assessed whether famotidine improved inflammation and symptomatic recovery in outpatients with mild to moderate COVID-19.
Design Randomised, double-blind, placebo-controlled, fully remote, phase 2 clinical trial (NCT04724720) enrolling symptomatic unvaccinated adult outpatients with confirmed COVID-19 between January 2021 and April 2021 from two US centres. Patients self-administered 80 mg famotidine (n=28) or placebo (n=27) orally three times a day for 14 consecutive days. Endpoints were time to (primary) or rate of (secondary) symptom resolution, and resolution of inflammation (exploratory).
Results Of 55 patients in the intention-to-treat group (median age 35 years (IQR: 20); 35 women (64%); 18 African American (33%); 14 Hispanic (26%)), 52 (95%) completed the trial, submitting 1358 electronic symptom surveys. Time to symptom resolution was not statistically improved (p=0.4). Rate of symptom resolution was improved for patients taking famotidine (p<0.0001). Estimated 50% reduction of overall baseline symptom scores were achieved at 8.2 days (95% CI: 7 to 9.8 days) for famotidine and 11.4 days (95% CI: 10.3 to 12.6 days) for placebo treated patients. Differences were independent of patient sex, race or ethnicity. Five self-limiting adverse events occurred (famotidine, n=2 (40%); placebo, n=3 (60%)). On day 7, fewer patients on famotidine had detectable interferon alpha plasma levels (p=0.04). Plasma immunoglobulin type G levels to SARS-CoV-2 nucleocapsid core protein were similar between both arms.
Conclusions Famotidine was safe and well tolerated in outpatients with mild to moderate COVID-19. Famotidine led to earlier resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity. Additional randomised trials are required.
-
Conclusions Famotidine was safe and well tolerated in outpatients with mild to moderate COVID-19.
It makes no sense to use marginally working drugs as primary treatment agents. Nasal and throat iodine solutions for killing all first stage virus are highly efficient. Ivermectin works perfectly with Omicron and of course prepare yourself with V-D3 (3-5000IU0s/day + 200mg V-K2) and zinc, max 25mg/day.
And always check the professional doctors site/protocols and find a free agent doctor willing to treat you:: https://covid19criticalcare.com/covid-19-protocols/
Only fools kill themselves with CoV-19 or a CoV-19 gene-therapy.
-
Efficacy and Safety of a Phytopharmaceutical Drug Derived from Cocculus hirsutus in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial
Efficacy and Safety of a Phytopharmaceutical Drug Derived from Cocculus hirsutus in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial - Infectious Diseases and TherapyIntroduction There is an urgent need for an effective, oral therapy for COVID-19. Purified aqueous extract of Cocculus hirsutus (AQCH) has shown robust…link.springer.comAbstract
Introduction
There is an urgent need for an effective, oral therapy for COVID-19. Purified aqueous extract of Cocculus hirsutus (AQCH) has shown robust antiviral activity in in vitro studies. We aimed to evaluate the efficacy and safety of AQCH plus standard of care in hospitalized patients with moderate COVID-19.
Methods
In an open-label, multicenter, randomized controlled trial conducted in India, eligible patients (aged 18–75 years) were randomized (1:1) to receive AQCH 400 mg orally three times a day plus standard of care (AQCH group) or standard of care alone (control group) for 10 days. Primary endpoint was the proportion of patients showing clinical improvement by day 14. Time to clinical improvement, time to viral clearance, and duration of hospitalization were secondary endpoints.
Results
A total of 210 patients were randomized. By day 14 most patients in both groups showed clinical improvement [difference − 0.01 (95% CI − 0.07 to 0.05); p = 1.0]. Median time to clinical improvement was 8 days (IQR 8–11) in the AQCH group versus 11 days (IQR 8–11) in the control group [HR 1.27 (95% CI 0.95–1.71); p = 0.032]. Time to viral clearance and duration of hospitalization were also significantly shorter in the AQCH group (p = 0.0002 and p = 0.016, respectively). AQCH was well tolerated, with no safety concerns identified.
Conclusions
AQCH significantly reduced time to clinical improvement, time to viral clearance, and duration of hospitalization. In a pandemic, this has significant potential to decrease healthcare resource utilization and increase hospital bed availability. Further investigation of the therapeutic potential of AQCH in patients with COVID-19 is warranted.
Trial Registration
Clinical Trials Registry – India (CTRI/2020/05/025397)
Cocculus hirsutus (L.) W.Theob. (Menispermaceae): A Review on Traditional Uses, Phytochemistry and Pharmacological Activities
Cocculus hirsutus (L.) W.Theob. (Menispermaceae): A Review on Traditional Uses, Phytochemistry and Pharmacological ActivitiesBackground:Cocculus hirsutus (L.) W.Theob. (Menispermaceae) is a perennial climber distributed mostly in tropical and subtropical areas. The main aim of this…www.ncbi.nlm.nih.gov -
UK:: Week 8 report :: https://assets.publishing.serv…lance_report_-_week-8.pdf
Week after weeks things get more ugly for vaccinated only. Age <30 dies at least 2x more often than unvaxx as this group is > 70% recovered now. Same for Age 80+. There no longer any group that shows a vaccine effect for death protection.
Dramatic is the rate for hospitalization, that now is up to 3x higher for some vaccinated groups (age< 40 with up to 80% recovered at least.)
Omicron now shows what most likely will happen with all future mutations. It will be a pandemic of "vaccinated" only....
-
The India vaccine only killer state of Kerala switches one gear up to deliver now 3/4 of all India CoV-19 deaths...
https://www.mygov.in/covid-19 (As of 27.2.2022)
-
Presumably the N.India and African states (except S. Africa) have a widespread use of traditional medicines such as Cocculus hirsutus and Nigella sativa, amongst an unknown range of other traditional medicines. This is probably why they are so healthy even though their diets are poor as limited by their economic/political circumstances. Western medicine has a lot to learn from their practising herbalist doctors!
-
Presumably the N.India and African states (except S. Africa) have a widespread use of traditional medicines such as Cocculus hirsutus and Nigella sativa, amongst an unknown range of other traditional medicines. This is probably why they are so healthy even though their diets are poor as limited by their economic/political circumstances. Western medicine has a lot to learn from their practising herbalist doctors!
Don't forget sutherlandia, it's used extensively across Africa for cancer and HIV and being trialed for covid
-
traditional medicines such as Cocculus hirsutus and Nigella sativa,
Also traditional Japanese mixtures contain black cumin... Look at the Japanese death rate...
If you have a starting throat problem Nigella Sative works perfectly. Take a half filled tea spoon seeds, chew it to press the oil out and softly swallow it over the throat.
-
Study shows young, healthy adults died from COVID-19 due to ECMO shortage
Study shows young, healthy adults died from COVID-19 due to ECMO shortageNearly 90 percent of COVID-19 patients who qualified for, but did not receive, ECMO (extracorporeal membrane oxygenation) due to a shortage of resources during…www.eurekalert.orgNearly 90 percent of COVID-19 patients who qualified for, but did not receive, ECMO (extracorporeal membrane oxygenation) due to a shortage of resources during the height of the pandemic died in the hospital, despite being young with few other health issues, according to a study published in the American Journal of Respiratory and Critical Care Medicine.
The Vanderbilt University Medical Center (VUMC) study, led by Whitney Gannon, MSN, director of Quality and Education for the Vanderbilt Extracorporeal Life Support Program (ECLS), analyzed the total number of patients referred for ECMO in one referral region between Jan. 1, 2021, and Aug. 31, 2021.
Approximately 90% of patients for whom health system capacity to provide ECMO was unavailable died in the hospital, compared to 43% mortality for patients who received ECMO, despite both groups having young age and limited comorbidities.
“Even when saving ECMO for the youngest, healthiest and sickest patients, we could only provide it to a fraction of patients who qualified for it,” Gannon said. “I hope these data encourage hospitals and federal authorities to invest in the capacity to provide ECMO to more patients.”
Once a patient was determined to be medically eligible to receive ECMO, a separate assessment was performed of the health system’s resources to provide ECMO.
When health system resources — equipment, personnel and intensive care unit beds —were not available, the patient was not transferred to an ECMO center and did not receive ECMO.
Among 240 patients with COVID-19 referred for ECMO, 90 patients (37.5%) were determined to be medically eligible to receive ECMO and were included in the study. The median age was 40 years and 25 (27.8%) were female.
For 35 patients (38.9%), the health system capacity to provide ECMO at a specialized center was available; for 55 patients (61.1%), the health system capacity to provide ECMO at a specialized center was unavailable.
Death before hospital discharge occurred in 15 of the 35 patients (42.9%) who received ECMO, compared with 49 of the 55 patients (89.1%) who did not receive ECMO.
“Throughout the pandemic, it has been challenging for many outside of medicine to see the real-world impact of hospitals being ‘strained’ or ‘overwhelmed,’” said co-author Matthew Semler, MD, assistant professor of Medicine at VUMC. “This article helps make those effects tangible. When the number of patients with COVID-19 exceeds hospital resources, young, healthy Americans die who otherwise would have lived.”
In total, the risk of death for patients who received ECMO at a specialized center was approximately half of those who did not.
“Because some patients die despite receiving ECMO, there has been debate about how much benefit it provides. This study shows the answer is a huge benefit,” said senior author Jonathan Casey, MD, assistant professor of Medicine at VUMC.
“This data suggests that, on average, providing ECMO to two patients will save a life and give a young person the potential to live for decades,” he said.
The study was funded by NIH National Heart, Lung, and Blood Institute grants K23HL153584 and K23HL143053.
-
I'd say this headline is a signal from the government that the pandemic is over! Can't have half of Congress wearing masks over a year into Biden presidency!!!
Members of Congress can attend State of the Union without masks: Live COVID updates
